ArticleRenal failure2026
Post-transplant anemia as a persistent risk factor for graft dysfunction in kidney transplant recipients.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-transplant anemia (PTA) is associated with adverse graft outcomes after kidney transplantation. However, it remains unclear whether persistent anemia despite erythropoiesis-stimulating agent (ESA) therapy is associated with long-term graft dysfunction in routine clinical practice.
methodsThis single-center retrospective study included 323 kidney transplant recipients followed at Masuko Kinen Hospital, Japan, from 2019 to 2021. The primary analysis used a linear mixed-effects model with repeated averaged estimated glomerular filtration rate (eGFRave) measurements over 2 years, treating hemoglobin (Hb) as a time-updated covariate. Supportive analyses evaluated 2-year change in eGFRave in the overall cohort and a propensity score-matched cohort.
resultsRecipients receiving ESA therapy had lower Hb levels and worse baseline kidney function than those not receiving ESA therapy. In the primary linear mixed-effects model, eGFRave declined over time (
conclusionPersistent PTA, rather than ESA use itself, was associated with graft function decline in kidney transplant recipients. Hb likely reflects underlying graft pathology, inflammation, or ESA resistance rather than being directly causal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.